Breaking News

Evotec Earns Boehringer Research Milestone

September 30, 2013

Oncology molecule moves to Phase I trials

Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim triggering a €2.0 million payment to Evotec. The milestone was for the transition of an oncology molecule into Phase I clinical trials.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, "This is a very important 19th milestone for Evotec in our collaboration with Boehringer Ingelheim, as it represents the first oncology compound to progress into Phase I studies. The collaboration continues to drive value for both companies."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems